University Medical Center Utrecht
Utrecht, Netherlands
NCT Number: NCT05310604
Rationale: Primary antibody deficiencies (PAD) encompass a group of rare heterogeneous diseases. The clinical presentation may vary widely, including infectious and autoimmune symptoms and increased risk of malignancy. Due to the rarity of the diseases and this wide array of symptoms there is often a delay in diagnosis, of up to 12 years on average1-4. Timely diagnosis of PAD reduces morbidity, mortality and health care costs as effective therapies are available. The currently available screening systems for the broader group of primary immunodeficiencies (PID) have been shown to have poor diagnostic performance5-10 and are time consuming. We have thus developed an algorithm to screen patient records in a primary care setting for risk factors specifically for PAD. Patients with a high risk may undergo a laboratory assessment and referral if necessary, thus reducing the diagnostic delay of PAD. The aim of the current study is to validate this algorithm.
Objective:
Main objective: to validate a screening algorithm for PAD in a primary care setting in the Netherlands.
Study design: Mono-centre cohort study based on regular care data
Study population: Primary care patients aged 12-70 years with the 100 highest scores based on our algorithm.
Looking for future studies?
Notify Me12 year–70 year
All sexes
Observational
Utrecht, Netherlands
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single blood withdrawal for determination of immunoglobulin levels
Time frame: measurement december 2022
UMC Utrecht
Other
Acronym: GP-PAD II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05321407
Bruton type agammaglobulinemia, COVID-19
St. Petersburg, Florida, United States
View Trial DetailsNCT07076446
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Litchfield Park, Arizona, United States
View Trial DetailsNCT03238079
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Los Angeles, California, United States
View Trial DetailsNCT07004803
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Karaman, Turkey (Türkiye)
View Trial Details